Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a ‘no-fly zone’?

References

• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–682.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–1076.
   PubMed Web of Science ®Google Scholar
• Falkson CB, Vella ET, Yu E, et al. Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18:105–121.
   PubMed Web of Science ®Google Scholar
• Loganadane G, Martinetti F, Mercier O, et al. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a critical literature review of predictive factors of relapse. Cancer Treat Rev. 2016;50:240–246.
   PubMed Web of Science ®Google Scholar
• Radiation Therapy Oncology Group RTOG 0236. A Phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I/II non-small cell lung cancer. 2014. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study
   Google Scholar
• NRG Oncology RTOG 0813. Seamless Phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. 2014. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study
   Google Scholar
• Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:967–971.
   PubMed Web of Science ®Google Scholar
• Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90:1168–1176.
   PubMed Web of Science ®Google Scholar
• Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 2009;66:89–93.
   PubMed Web of Science ®Google Scholar
• Wang HH, Zaorsky NG, Meng MB, et al. Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget. 2016;7:18135–18145.
   Google Scholar
• Meng MB, Wang HH, Zaorsky NG, et al. Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget. 2015;6:15690–15703.
   Google Scholar
• Common Terminology Criteria for Adverse Events and Common Toxicity Criteria. National Cancer Institute Cancer Therapy Evaluation Program. 2009. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Corradetti MN, Haas AR, Rengan R. Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med. 2012;366:2327–2329.
   PubMed Web of Science ®Google Scholar
• Rowe BP, Boffa DJ, Wilson LD, et al. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012;7:1394.
   PubMedGoogle Scholar
• Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer. 2015;89:50–56.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15:e623.
   PubMed Web of Science ®Google Scholar
• Orecchia R, Surgo A, Muto M, et al. VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions. Ecancermedicalscience. 2016;10:677.
   PubMed Web of Science ®Google Scholar
• Garibaldi C, Piperno G, Ferrari A, et al. Translational and rotational localization errors in cone-beam CT based image-guided lung stereotactic radiotherapy. Phys Med. 2016;32:859–865.
   PubMed Web of Science ®Google Scholar
• El-Sherief AH, Lau CT, Wu CC, et al. International association for the study of lung cancer (IASLC) lymph node map: radiologic review with CT illustration. RadioGraphics. 2014;34:1680–1691.
   PubMed Web of Science ®Google Scholar
• Timmerman RD. An overview of hypofractionation and introduction to this issue of Seminars in Radiation Oncology. Semin Radiat Oncol. 2008;18:215–222.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Ciardo D, Ferrario S, et al. No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. Br J Radiol. 2016;89:20150985.
   PubMed Web of Science ®Google Scholar
• Trodella L, Trodella L, Granone P, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;62:11–19.
   PubMed Web of Science ®Google Scholar
• Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected non small cell lung carcinoma. Groupe d’Etude et de Traitement des Cancers Bronchiques. Cancer. 1999;86:265–273.
   PubMed Web of Science ®Google Scholar
• Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–692.
   PubMed Web of Science ®Google Scholar
• Duijm M, Schillemans W, Aerts JG, et al. Dose and volume of the irradiated main bronchi and related side effects in the treatment of central lung tumors with stereotactic radiotherapy. Semin Radiat Oncol. 2016;26:140–148.
   PubMed Web of Science ®Google Scholar
• Xue J, Kubicek G, Patel A, et al. Validity of current stereotactic body radiation therapy dose constraints for aorta and major vessels. Semin Radiat Oncol. 2016;26:135–139.
   PubMed Web of Science ®Google Scholar
• Kimsey F, McKay J, Gefter J, et al. Dose-response model for chest wall tolerance of stereotactic body radiation therapy. Semin Radiat Oncol. 2016;26:129–134. doi: 10.1016/j.semradonc.2015.11.003
   PubMed Web of Science ®Google Scholar
• Stephans KL, Djemil T, Diaconu C, et al. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity. Int J Radiat Oncol Biol Phys. 2014;90:197–202.
   PubMed Web of Science ®Google Scholar
• Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631.
   PubMed Web of Science ®Google Scholar
• Taremi M, Hope A, Dahele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys. 2012;82:967–973.
   PubMed Web of Science ®Google Scholar